Article

COA Announces Opposition to Administration Nixing Part D Rebate Rule

Community Oncology Alliance's (COA's) executive director Ted Okon has released a statement expressing disappointment over the Trump administration’s decision to abandon a proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care.

Community Oncology Alliance's executive director Ted Okon has released a statement expressing disappointment over the Trump administration’s decision to abandon a proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care. According to Okon, the proposed rule would have lowered drug prices for patients by ensuring they receive the benefit of negotiated drug discounts. By nixing the proposed rule, the administration has handed a gift to pharmacy benefit managers (PBMs).

In the original plan’s announcement, President Donald Trump and HHS Secretary Alex Azar acknowledged that “nearly every drug company taking a January 2019 price increase announced that all of the increase was being paid to PBMs or insurers as rebates.”

Read the full press release.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Mansi Shah, MD
Dr Ibrahim Aldoss
Mansi Shah, MD
Dr John Mascarenhas
Merrill H. Stewart, MD
Dr John Mascarenhas
Dr Sundar Jagannath
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo